Glenmark Pharma shares trade lower as firm inks licensing pact with China's Hansoh Pharma for cancer drug

Glenmark Specialty SA, a wholly owned subsidiary of the company, has entered into an exclusive licence, collaboration and distribution agreement with Hansoh Pharma for Aumolertinib, a third-generation epidermal growth factor receptor tyrosine kinase inhibitor.

Under the terms of the agreement, Glenmark receives exclusive rights to develop and commercialise Aumolertinib across its licensed territories: the Middle East and Africa, Southeast & South Asia, Australia, New Zealand, Russia/CIS, and a few selected Caribbean countries covered by the agreement, the Mumbai-based firm said in a statement.

Hansoh Pharma will receive an upfront payment of low double-digit million USD, followed by potential regulatory and commercial milestone payments possibly cumulating to over $1 billion, in addition to tiered royalties on net sales in the licensed territories, it added.

"This collaboration reinforces our disciplined approach to expanding our innovative portfolio and widening access to advanced cancer care across key markets," Glenmark Pharmaceuticals Chairman and Managing Director Glenn Saldanha stated.

Aumolertinib, marketed as Ameile in China and Aumseqa in the United Kingdom and Europe, as a monotherapy, has received marketing authorisation from the UK MHRA.

Glenmark Pharmaceuticals is a research‐led, global pharmaceutical company, having a presence across branded, generic, and OTC segments, with a focus on therapeutic areas of respiratory, dermatology, and oncology. The company has 11 manufacturing facilities spread across four continents and operations in over 80 countries.

Glenmark Pharma share price

At 10:25 AM, Glenmark Pharma shares were trading at ₹1,959.50 apiece on the National Stock Exchange, falling 0.36%.

For a month’s time, the stock has rallied 5%, while the stock has gained 16.5% in 6 months. Since the beginning of 2025, shares of the firm have surged 21.5%.

Shares of Glenmark Pharma had hit a 52-week high of ₹2,284.80 on July 11, 2025, and a 52-week low of ₹1,275.50 on February 28, 2025.

The company has a total market capitalisation of ₹55,367.80 crore, according to data on the NSE.